Quest Diagnostics Incorporated (NYSE: DGX) is a Healthcare company (Medical - Diagnostics & Research) with a market capitalization of $28.8B. The Maz Rating grades it against the other companies in its sector.
Quest Diagnostics Incorporated's current Maz Rating and its five factor grades are for members: log in to see them.
At $262.21, Quest Diagnostics Incorporated trades at 25.8x trailing earnings, 2.4x sales and 3.8x book value, with an EV/EBITDA of 14.9. Over the last twelve months it generated about $11.8B of revenue and $1.1B of net income. It runs a gross margin of 33.1%, an operating margin of 14.6% and a net margin of 9.5%. It shows return on equity of 15.2%, return on invested capital of 8.5% and a free cash flow yield of 4.8%. On the balance sheet: a debt-to-equity ratio of 0.82 and a current ratio of 1.70. Over the past 52 weeks the share price ranged from $171.18 to $263.19, with a beta of 0.55.
Quest Diagnostics Incorporated pays a dividend yielding 1.29%, with 33% of earnings paid out. Its Maz Dividend Score is 3.37 out of 5, ranked against the other dividend payers in its sector (Safety 2.57, Growth 3.30, Yield 3.17, Consistency 4.02).
34 Wall Street analyst ratings cover the stock: 13 Buy, 18 Hold and 3 Sell, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Quest Diagnostics Incorporated (DGX) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 23.6% / 30% · (Cash+Inv) / Mkt Cap (36m) 3.52% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 23.6% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 3.00% / 33% · Receivables / Mkt Cap (36m) 6.44% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 23.6% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 3.00% / 33.33% · Receivables / Mkt Cap (24m) 6.44% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 38.0% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 3.33% / 33.33% · Receivables / Avg Assets (4Q) 9.50% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 36.5% / 33.33% · (Cash+ST Inv) / Total Assets 4.63% / 33.33% · (Cash+Recv) / Total Assets 14.6% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Quest Diagnostics Incorporated (DGX) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Quest Diagnostics Incorporated is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
Quest Diagnostics Incorporated reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.